RPL21

Across TCGA pan-cancer cohorts, RPL21 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated RPL21 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher RPL21 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPL21 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

UCEC, GBM, and CCRCC are the cancer types where RPL21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	1.000	0.424	.003	42	view →
GBM	DFS	Median	All	0.232	0.493	<.001	19	view →
CCRCC	OS	Tertile	All	0.710	0.921	.006	18	view →
PDAC	OS	Quartile	All	0.746	0.969	.019	9	view →
COAD	DFS	Median	III,IV	1.000	0.841	.041	6	view →
HNSC	OS	Median	All	1.000	0.959	.023	6	view →
LUAD	OS	Median	II,III,IV	0.449	0.893	.023	4	view →
LSCC	DFS	Median	All	0.793	0.626	.037	4	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RPL21–UCEC (DFS)

Open the UCEC breakdown →